

# Junji Hiraga

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3279151/publications.pdf>

Version: 2024-02-01

16  
papers

362  
citations

1478505

6  
h-index

1372567

10  
g-index

16  
all docs

16  
docs citations

16  
times ranked

579  
citing authors

#	ARTICLE	IF	CITATIONS
1	Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. <i>Blood</i> , 2009, 113, 4885-4893.	1.4	217
2	Epigenetic Regulation of CD20 Protein Expression in a Novel B-Cell Lymphoma Cell Line, RRBL1, Established from a Patient Treated Repeatedly with Rituximab-Containing Chemotherapy. <i>International Journal of Hematology</i> , 2007, 86, 49-57.	1.6	43
3	Escape mechanisms from antibody therapy to lymphoma cells: Downregulation of CD20 mRNA by recruitment of the HDAC complex and not by DNA methylation. <i>Biochemical and Biophysical Research Communications</i> , 2009, 390, 48-53.	2.1	42
4	A low birth weight infant with no malformations delivered by a primary immune thrombocytopenia patient treated with eltrombopag. <i>International Journal of Hematology</i> , 2018, 108, 109-111.	1.6	20
5	Relationship Between Post-Translational Modification of CD20 Protein and the Responsiveness to Rituximab Treatment. <i>Blood</i> , 2008, 112, 2667-2667.	1.4	19
6	Expression of programmed cell death ligand 1 by immune cells in the microenvironment is a favorable prognostic factor for primary diffuse large B-cell lymphoma of the central nervous system. <i>Neuropathology</i> , 2021, 41, 99-108.	1.2	8
7	Successful immunosuppressive and iron chelation therapy for a severe aplastic anemia patient undergoing hemodialysis due to chronic renal failure. <i>International Journal of Hematology</i> , 2011, 93, 555-557.	1.6	6
8	Partial restoration of CD20 protein expression and rituximab sensitivity after treatment with azacitidine in CD20-negative transformed diffuse large B cell lymphoma after using rituximab. <i>Annals of Hematology</i> , 2018, 97, 2253-2255.	1.8	5
9	Discrepancy of CD20 Protein Expression In IHC and FCM Analyses In Primary B-Cell Lymphoma: Relationship Between FCM-Negative Phenotype and Rituximab Binding with Lymphoma Cells. <i>Blood</i> , 2010, 116, 5087-5087.	1.4	1
10	CD20 Protein Immunohistochemistry-Positive/Flow Cytometry-Negative Diffuse Large B-Cell Lymphoma—Analyses of the Molecular Mechanisms and Rituximab Effectiveness. <i>Blood</i> , 2011, 118, 2659-2659.	1.4	1
11	Composite Lymphoma Comprising Extranodal NK/T-Cell Lymphoma and Diffuse Large B-Cell Lymphoma. <i>Case Reports in Hematology</i> , 2018, 2018, 1-4.	0.4	0
12	Nivolumab Effective for Gastric and Lung Cancers but Not for Multiple Myeloma in a Multiple Primary Cancer Patient. <i>Case Reports in Hematology</i> , 2021, 2021, 1-4.	0.4	0
13	MS4A1 (CD20) Gene Expression Is Down-Regulated by Recruiting the Histone Deacetylase Protein Complex to the Promoter in the CD20-Negative B-Lymphoma Cells After Treatment with Rituximab. <i>Blood</i> , 2009, 114, 1286-1286.	1.4	0
14	CD20-Negative Phenotypic Change In B-Cell Lymphoma Cells After Using Rituximab: Possibility of a Particular Clinicopathologic Phenomenon Post-Rituximab Extranodal CD20-Negative Lymphoma. <i>Blood</i> , 2010, 116, 2874-2874.	1.4	0
15	Clinical Significance of Genetic Mutations of CD79B, CARD11, MYD88, and EZH2 Genes in Diffuse Large B-Cell Lymphoma Patients. <i>Blood</i> , 2011, 118, 2633-2633.	1.4	0
16	Retention of Slow-Cycling CD34+ cells During Imatinib Treatment and Rapid Decline After 2nd ABL-TKI Treatment in Ph+ Leukemia Cells. <i>Blood</i> , 2011, 118, 641-641.	1.4	0